DAY ONE BIOPHARMACEUTICALS I's ticker is DAWN and the CUSIP is 23954D109. A total of 129 filers reported holding DAY ONE BIOPHARMACEUTICALS I in Q3 2023. The put-call ratio across all filers is 2.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,944,131 | -31.5% | 158,446 | -33.3% | 0.00% | – |
Q2 2023 | $2,838,185 | +15.4% | 237,704 | +29.2% | 0.00% | – |
Q1 2023 | $2,458,996 | +30.9% | 183,919 | +110.8% | 0.00% | – |
Q4 2022 | $1,877,942 | -12.7% | 87,265 | -18.8% | 0.00% | – |
Q3 2022 | $2,151,000 | +224.9% | 107,405 | +190.0% | 0.00% | – |
Q2 2022 | $662,000 | +308.6% | 37,040 | +125.1% | 0.00% | – |
Q1 2022 | $162,000 | -31.4% | 16,453 | +17.8% | 0.00% | – |
Q4 2021 | $236,000 | +237.1% | 13,964 | +370.6% | 0.00% | – |
Q3 2021 | $70,000 | +29.6% | 2,967 | +25.0% | 0.00% | – |
Q2 2021 | $54,000 | – | 2,374 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Canaan Partners XI LLC | 6,964,301 | $139,495,000 | 56.26% |
PATHWAY CAPITAL MANAGEMENT, LP | 403,127 | $8,075,000 | 25.88% |
Atlas Venture Life Science Advisors, LLC | 8,169,171 | $163,628,000 | 18.06% |
RA Capital Management | 7,040,622 | $141,024,000 | 3.01% |
COMMODORE CAPITAL LP | 739,661 | $14,815,000 | 2.38% |
Nicholas Investment Partners, LP | 757,407 | $15,171,000 | 1.41% |
Boxer Capital, LLC | 1,189,943 | $23,835,000 | 1.34% |
Parkman Healthcare Partners LLC | 212,191 | $4,250,000 | 1.21% |
TANG CAPITAL MANAGEMENT LLC | 400,000 | $8,012,000 | 0.98% |
Samsara BioCapital, LLC | 196,425 | $3,934,000 | 0.92% |